US medical device regulators have released a draft guidance detailing how sponsors and manufacturers of so-called "custom" medical devices can comply with US Food and Drug Administration (FDA) regulations.
Custom medical devices can be thought of as being similar to products made by pharmaceutical compounders: They are similar to already-approved devices, but are custom-made to the specifications of a single patient based on their prescribed needs as determined by a healthcare professional.
Like compounded products, custom devices are mostly exempt from regulation, and are not required to seek premarket approval or clearance. However, they are required to meet standards for good manufacturing practices (GMPs) under FDA's quality system regulation (QSR, 21 CFR 820).
The devices are defined per 21 CFR 812.3(b) as devices not being generally available, not available in finished form, deviated for the needs of a specific patient, not advertised for commercial distribution and intended for a specific patient.
But as with pharmaceutical compounding, the line between a product that requires approval and one allowed to bypass regulatory approval is not always clear. In April 2009, for example, FDA won a case before the US Court of Appeals for the Eleventh Circuit against manufacturer Endotec, which the court found was manufacturing devices and marketing them as "custom" when they were actually subject to FDA regulation. Though FDA won the case, The Gray Sheet reported that left unanswered by the courts was an important question: What line separates a custom device from a commercial one?
The issue was controversial-and important-enough to warrant inclusion in the Food and Drug Administration Safety and Innovation Act (FDASIA) of 2012, Section 617 of which clarified the definition of "Custom Devices" and called upon FDA to issue final guidance to clarify requirements by August 2014.
Since then, FDA has listed the guidance as among its most important, but a planned August 2013 release date for the guidance came and went.
But after a long wait, FDA has now finally released the text of its draft guidance for industry: Custom Device Exemption.
In it, FDA focuses on some of the more difficult and controversial provisions of the custom device regulation that have long troubled manufacturers.
For example, Section 520(b) of the Federal Food, Drug and Cosmetic Act (FD&C Act)-the section of the law that governs custom devices-maintains that manufacturers can make no more than five units per year of a particular device type. Otherwise, the law, modified by FDASIA, states they must seek premarket approval.
FDA said that this "five units" clause will be measured in individual cases, such as five new patients or five new physicians. "The five-unit limitation includes all devices provided by a manufacturer to, and remaining in the possession of, the ordering physician and/or the patient," FDA added. Extra units manufactured to accommodate potential sizing concerns will not count toward the total so long as the extras do not enter commercial distribution and are destroyed, FDA continued.
The remainder of the guidance focuses on two aspects: Assorted questions and answers, and the annual reporting requirements for manufacturers of custom devices.
Some notable answers from the guidance:
The guidance also explains the requirements associated with submitting an annual report, which should include the number of patients who received a new device or a revised version of an existing device, the number of devices manufactured and distributed, and other relevant information.
Comments are due by 14 March 2014.
We have completed our migration to a new platform and are pleased to introduce the updated site.
What to expect: If you have an existing login, please RESET YOUR PASSWORD before signing in. After you log in for the first time, you will be prompted to confirm your profile preferences, which will be used to personalize content.
We encourage you to explore the new website and visit your updated My RAPS page. If you need assistance, please review our FAQ page.
We welcome your feedback. Please let us know how we can continue to improve your experience.